- Report
- May 2026
- 145 Pages
Global
From €3536EUR$3,950USD£3,036GBP
- Report
- May 2026
- 148 Pages
Global
From €3536EUR$3,950USD£3,036GBP
- Report
- September 2025
- 150 Pages
Global
From €4342EUR$4,850USD£3,728GBP
- Report
- May 2026
- 400 Pages
Global
From €4430EUR$4,949USD£3,804GBP
- Report
- September 2025
- 150 Pages
Global
From €3984EUR$4,450USD£3,420GBP
- Report
- April 2026
- 137 Pages
Global
From €3500EUR$4,188USD£3,110GBP
- Report
- April 2026
- 128 Pages
Global
From €3500EUR$4,188USD£3,110GBP
- Report
- April 2026
- 155 Pages
Global
From €4342EUR$4,850USD£3,728GBP
- Report
- October 2025
- 140 Pages
Global
From €4342EUR$4,850USD£3,728GBP
- Report
- November 2025
- 150 Pages
Global
From €4342EUR$4,850USD£3,728GBP
- Report
- November 2025
- 150 Pages
Global
From €4342EUR$4,850USD£3,728GBP
- Report
- November 2025
- 150 Pages
Global
From €4342EUR$4,850USD£3,728GBP
- Report
- October 2025
- 150 Pages
Global
From €4342EUR$4,850USD£3,728GBP
- Newsletter
- August 2026
- 88 Pages
Global
€1180EUR$1,318USD£1,013GBP
- Report
- June 2026
- 52 Pages
Global
From €6714EUR$7,500USD£5,764GBP
- Report
- December 2025
- 52 Pages
Global
From €6714EUR$7,500USD£5,764GBP
- Report
- October 2025
- 96 Pages
Global
From €4029EUR$4,500USD£3,459GBP
- Report
- October 2025
- 100 Pages
Middle East
From €4029EUR$4,500USD£3,459GBP
- Report
- November 2022
- 141 Pages
Global
From €4431EUR$4,950USD£3,804GBP
- Report
- December 2024
- 581 Pages
Global
From €4431EUR$4,950USD£3,804GBP

Lymphoma is a type of hematological malignancy that originates in the lymphatic system. It is characterized by the uncontrolled growth of lymphocytes, a type of white blood cell. Lymphomas can be either Hodgkin's or non-Hodgkin's, and can be either indolent or aggressive. Treatment options for lymphoma include chemotherapy, radiation therapy, stem cell transplantation, and targeted therapies.
The lymphoma market is a subset of the larger hematology market, which includes treatments for a variety of blood-related diseases. The lymphoma market is driven by the increasing prevalence of the disease, as well as the development of new treatments.
Companies in the lymphoma market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Gilead Sciences, Novartis, and Pfizer. Show Less Read more